Neoadjuvant therapy with ipilimumab and nivolumab for stage III malignant melanoma - a case report

被引：0
|
作者：
Hansen, I. [1 ]
Heidrich, I. [1 ]
Belz, S. [1 ]
Noebel, C. [1 ]
Geidel, G. [1 ]
Hildebrandt, L. [1 ]
Schneider, S. W. [1 ]
Gebhardt, C. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Klin Dermatol & Venerol, Hamburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP096
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [31] Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
    Versluis, Judith M.
    Sikorska, Karolina
    Rozeman, Elisa A.
    Menzies, Alexander M.
    Eriksson, Hanna
    Klop, W. Martin. C.
    Saw, Robyn P. M.
    Van de Wiel, Bart A.
    Scolyer, Richard A.
    Van Thienen, Johannes V.
    Mallo, Henk
    Gonzalez, Maria
    Acosta, Alex Torres
    Grijpink-Ongering, Lindsay G.
    Van der Wal, Anja
    Haanen, John B. A. G.
    Van Akkooi, Alexander Christopher Jonathan
    Long, Georgina V.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report
    Suzuki, Yoshiharu
    Ishiguro, Shingo
    Shimada, Hirokazu
    Ohgami, Masahiro
    Suzuki, Mika
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (06) : 633 - 638
  • [33] Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report
    Velazquez, Adan Martin Cuevas
    Ng, Wern Lynn
    Martinez, Evelyn J. Calderon
    Yeruva, Sri Lakshmi Hyndavi
    AMERICAN JOURNAL OF CASE REPORTS, 2023, 24
  • [34] Regredience the Metastases of malignant Melanoma in the advanced Stage by Therapy with Nivolumab
    Pediaditi, P.
    Lutze, S.
    Arnold, A.
    Junger, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 33 - 33
  • [35] Ipilimumab/nivolumab/relatlimabHyperprogression of metastatic vaginal melanoma and myocarditis: case report
    Reactions Weekly, 2021, 1852 (1) : 248 - 248
  • [36] Neoadjuvant Ipilimumab/Nivolumab combination in locally advanced or oligometastatic melanoma
    Ferrucci, Pier Francesco
    Lanfrancone, Luisa
    Mazzarella, Luca
    Nezi, Luigi
    Duso, Bruno Achutti
    Manzo, Teresa
    Lotti, Fiorenza
    Gandini, Sara
    Orsolini, Gianmarco
    Pennacchioli, Elisabetta
    Gnagnarella, Patrizia
    Fierro, Maria Teresa
    Senetta, Rebecca
    Riviello, Concetta
    Caliendo, Virginia
    Quaglino, Pietro
    Mazzarol, Giovanni
    Bonizzi, Giuseppina
    Cocorocchio, Emilia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
  • [37] Ipilimumab/nivolumab/pembrolizumabHyperprogression of melanoma with development of new metastases: case report
    Reactions Weekly, 2017, 1680 (1) : 193 - 193
  • [38] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
    Eggermont, A. M. M.
    Chiarion-Sileni, V.
    Grob, J. -J.
    Dummer, R.
    Wolchok, J. D.
    Schmidt, H.
    Hamid, O.
    Robert, C.
    Ascierto, P. A.
    Richards, J. M.
    Lebbe, C.
    Ferraresi, V.
    Smylie, M.
    Weber, J. S.
    Maio, M.
    Bastholt, L.
    Mortier, L.
    Thomas, L.
    Tahir, S.
    Hauschild, A.
    Hassel, J. C.
    Hodi, F. S.
    Taitt, C.
    de Pril, V.
    de Schaetzen, G.
    Suciu, S.
    Testori, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1845 - 1855
  • [39] Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab
    Tahsin M. Khan
    Martha E. Teke
    Giorgos C. Karakousis
    John T. Miura
    Robert M. Brody
    Jonathan M. Hernandez
    Tara C. Mitchell
    Annals of Surgical Oncology, 2022, 29 : 2771 - 2772
  • [40] Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
    Reijers, I.
    Dimitriadis, P.
    Menzies, A. M.
    Kapiteijn, E.
    Van der Veldt, A. A. M.
    Suijkerbuijk, K. P. M.
    Hospers, G. A. P.
    Van Houdt, W.
    Saw, R.
    Broeks, A.
    Cornelissen, S.
    Grijpink-Ongering, L.
    Pennington, T.
    Colebatch, A.
    de Wiel, B. van
    Scolyer, R.
    van Akkooi, A. C. J.
    Long, G. V.
    Blank, C. U.
    ANNALS OF ONCOLOGY, 2023, 34 : S660 - S660
12345